Reimbursed Care Access in Suriname

Currently classified as a strictly controlled substance under national drug‑scheduling laws, with no authorized medical use outside of approved clinical research. The Surinamese 'Wet Verdovende Middelen' operates by lists that place hallucinogens/psychotropic substances in the most restrictive category; national reporting and commentary around enforcement indicate psilocybin/magic mushroom compounds are treated as banned and subject to criminal penalties. # #

Currently classified as a strictly controlled substance under national drug‑scheduling laws, with no authorized medical use outside of approved clinical research. Public sources and legal summaries for Suriname list MDMA/XTC among Schedule I/hard drugs subject to prosecution and significant custodial sentences. # #

There is no evidence of a national regulatory approval, reimbursement pathway, or clinical program for esketamine nasal spray (Spravato) in Suriname; esketamine-specific specialty deployment (for TRD) requires regulatory approval and local pharmacare listing which is not available in Surinamese public sources. Clinically, international approvals (e.g., EMA/FDA) do not automatically extend to Suriname, and a search of Suriname medicine lists and public policy material shows no listing or reimbursement scheme for esketamine. For context, ketamine (the racemate) is present on Suriname's essential medicines/anesthesia lists, but that does not imply esketamine nasal spray is authorized or reimbursed locally. # #

Ketamine is an accepted and available anesthetic agent in Suriname's national medicine listings and hospital formularies for use in anesthesia and emergency medicine; it appears on regional/PAHO annotated medicine lists and local insurance/pharmaceutical formularies as an injectable anesthetic, indicating routine medical availability for legitimate clinical indications (e.g., general anesthesia, analgesia in emergency settings). Evidence: PAHO annotated medicine list for Suriname explicitly lists ketamine injection as a general anesthetic available in the country. # Additionally, a Surinamese insurer/pharmaceutical formulary (Self Reliance) and other national medicine documents reference ketamine 50 mg/mL injectable preparations, supporting that ketamine is procured and used in medical settings and may be reimbursed when supplied under standard hospital/insurer arrangements for anesthesia. # Practical notes on reimbursement and access: Suriname’s health system is mixed public/private; essential/hospital medicines (including anesthetics) are typically procured centrally or by hospitals and may be covered under inpatient care billing or private insurance packages, rather than through a dedicated psychedelic‑therapy reimbursement pathway. There is no evidence of ketamine being reimbursed in Suriname for off‑label outpatient psychiatric use (e.g., treatment‑resistant depression) via an established regulatory or payer program — its use is confined to recognized medical indications such as anesthesia. #

Currently classified as a strictly controlled substance under national drug‑scheduling laws, with no authorized medical use outside of approved clinical research. DMT and related plant/derived tryptamines are treated as controlled hallucinogens under Suriname’s drug law framework, and public legal guides indicate possession or trafficking can lead to severe penalties. # #

Currently classified as a strictly controlled substance under national drug‑scheduling laws, with no authorized medical use outside of approved clinical research. Suriname’s scheduling approach includes broad control of psychotropic hallucinogens; 5‑MeO‑DMT is not recognized as having any sanctioned medical pathway locally. # #

Currently classified as a strictly controlled substance under national drug‑scheduling laws, with no authorized medical use outside of approved clinical research. There is no public information that Suriname permits ibogaine for addiction treatment or any regulated medical program; control and enforcement reporting indicate it falls under prohibited psychotropic/controlled substances. # #

Currently classified as a strictly controlled substance under national drug‑scheduling laws, with no authorized medical or religious exception outside of approved clinical research. Although Suriname is in a region where traditional plant medicines occur, Surinamese law treats DMT‑containing preparations and their active constituents under restrictive national lists; no recognized regulatory exemption or reimbursed therapeutic framework for ayahuasca is documented. # #

Currently classified as a strictly controlled substance under national drug‑scheduling laws, with no authorized medical use outside of approved clinical research. Mescaline and mescaline‑containing cacti are not documented as legal for consumption or medical practice in Suriname; extracted mescaline is treated as a prohibited psychotropic. # #

Currently classified as a strictly controlled substance under national drug‑scheduling laws, with no authorized medical use outside of approved clinical research. Substituted phenethylamines (e.g., 2C‑series) fall within the broad psychotropic controls and are treated as prohibited substances subject to criminal enforcement. # #